Detalhe da pesquisa
1.
Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden.
Pharmacoeconomics
; 38(7): 747-764, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32239480
2.
Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland.
Eur J Hosp Pharm
; 20(4): 227-231, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23888248